help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Turner, J. J. O.
Right arrow Articles by Thakker, R. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Turner, J. J. O.
Right arrow Articles by Thakker, R. V.
The Journal of Clinical Endocrinology & Metabolism Vol. 87, No. 6 2688-2693
Copyright © 2002 by The Endocrine Society


The Impact of the Human Genome on Endocrinology: Original Articles

Frequent Occurrence of an Intron 4 Mutation in Multiple Endocrine Neoplasia Type 1

Jeremy J. O. Turner1, Poloko D. Leotlela2, Anna A. J. Pannett, Simon A. Forbes, J. H. Duncan Bassett, Brian Harding, Paul T. Christie, David Bowen-Jones, Sian Ellard, Andrew Hattersley, Charles E. Jackson, Richard Pope, Oliver W. Quarrell, Richard Trembath and Rajesh V. Thakker

Molecular Endocrinology Group, Nuffield Department of Clinical Medicine, University of Oxford (J.J.O.T., P.D.L., A.A.J.P., B.H., P.T.C., R.V.T.), Oxford, United Kingdom OX3 9DU; Medical Research Council Molecular Endocrinology Group, Medical Research Council Clinical Sciences Center, Imperial College School of Medicine, Hammersmith Hospital (J.J.O.T., A.A.J.P., S.A.F., J.H.D.B., B.H., P.T.C., R.V.T.), London, United Kingdom W12 0NN; Department of Medicine, Arrowe Park Hospital (D.B.-J.), Upton, Wirral, United Kingdom L49 5PE; Molecular Genetics Laboratory, Royal Devon and Exeter Hospital (Wonford) (S.E., A.H.), Exeter, United Kingdom EX2 5DW; Department of Medical Genetics, Henry Ford Hospital, Center for Molecular Medicine and Genetics (C.E.J.), Detroit, Michigan 48201; Airedale General Hospital (R.P.), Steeton, Keighley, West Yorkshire, United Kingdom BD20 6TD; North Trent Clinical Genetics Service, Sheffield Children’s Hospital (O.W.Q.), Western Bank, Sheffield, United Kingdom S10 2TH; and Department of Genetics, University of Leicester (R.T.), Leicester, United Kingdom LE1 7RH

Address all correspondence and requests for reprints to: Prof. R. V. Thakker, Molecular Endocrinology Group, Level 7, Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom OX3 9DU. E-mail: . rajesh.thakker{at}ndm.ox.ac.uk

Abstract

MEN1 is an autosomal dominant disorder characterized by parathyroid, pituitary, and pancreatic tumors. The MEN1 gene is located on chromosome 11q13 and encodes a 610-amino acid protein. MEN1 mutations are of diverse types and are scattered throughout the coding region, such that almost every MEN1 family will have its individual mutation. To further characterize such mutations we ascertained 34 unrelated MEN1 probands and undertook DNA sequence analysis. This identified 17 different mutations in 24 probands (2 nonsense, 2 missense, 2 in-frame deletions, 5 frameshift deletions, 1 frameshift deletional-insertion, 3 frameshift insertions, 1 donor splice site mutation, and a g->a transition that resulted in a novel acceptor splice site in intron 4). The intron 4 mutation was found in 7 unrelated families, and the tumors in these families varied considerably, indicating a lack of genotype-phenotype correlation. However, this intron 4 mutation is the most frequently occurring germline MEN1 mutation (~10% of all mutations), and together with 5 others at codons 83–84, 118–119, 209–211, 418, and 516, accounts for 36.6% of all mutations, a finding that indicates an approach for identifying the widely diverse MEN1 mutations.




This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
O Vierimaa, T M L Ebeling, S Kytola, R Bloigu, E Eloranta, J Salmi, E Korpi-Hyovalti, L Niskanen, A Orvola, E Elovaara, et al.
Multiple endocrine neoplasia type 1 in Northern Finland; clinical features and genotype phenotype correlation
Eur. J. Endocrinol., September 1, 2007; 157(3): 285 - 294.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
A. Karhu and L. A. Aaltonen
Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update
Hum. Mol. Genet., April 15, 2007; 16(R1): R73 - R79.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
K J Bradley, B M Cavaco, M R Bowl, B Harding, A Young, and R V Thakker
Utilisation of a cryptic non-canonical donor splice site of the gene encoding PARAFIBROMIN is associated with familial isolated primary hyperparathyroidism
J. Med. Genet., August 1, 2005; 42(8): e51 - e51.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society